PubMed Health⌕ Search

Biomedical subjects

A Nago

Publications and source records attributed to A Nago.

6 recordsLinked to original sources
PubMed1992

[Sensitivity of the parietal cell to the effect of pentagastrin in men living at high altitude].

This study evaluates the response of the gastric mucosa to pentagastrin in a group (HAG) of 17 andean subjects compared to a similar group of 17 subjects at sea level (LAG). Both groups had normal fundic, body and antrum mucosa as demonstrated by endoscopic and histological means. Each group underwent two assays, the first one with a dose of 6 micrograms/kg and 72 hours later, the second administration with 3 micrograms/kg. In the HAG the acid response expressed as concentration and output was significantly greater with 6 micrograms/kg that with 3 micrograms/kg. In the LAG the difference was not statistically significant. The ANOVA analysis showed, for both determinations, free and total acidity, a different response pattern between the HAG and LAG for both doses. The response of both groups to the 3 micrograms/kg reveals a lesser sensitivity to pentagastrin of the parietal cell in HAG.

Adult↗
PubMed1990

[Famotidine in the treatment of duodenal peptic ulcer].

A multicenter, open study was designed to evaluate the efficacy and tolerability of a novel and potent H2 receptor antagonist, Famotidine, in the treatment of duodenal ulcer. Thirty-four patients with endoscopically proven active duodenal ulcer were treated with Famotidine, 40 mg, one tablet, at bedtime, for six weeks. Follow-up endoscopic exams were done every two weeks until ulcer healing was obtained. One patient was excluded from further analysis as he failed to follow the protocol. Healing rates achieved were 48.5%, 91% and 97% by the second, fourth and sixth week of treatment respectively. After 72 hours 52% of the patients were asymptomatic and 79% at the end of the first week of treatment. Famotidine was well tolerated, no clinical neither laboratory adverse events were observed during the study. Famotidine, a novel H2 receptor antagonist appears to be effective and well tolerated in the treatment of most patients with duodenal ulcer.

Adult↗
PubMed1989

[Villous adenoma: clinical, endoscopic and histopathologic aspects].

A ten years retrospective study of villous adenomas at the Arzobispo Loayza Hospital was carried out. 24 patients with this problem were found, the mean age was 62 years, clinical symptoms were: rectal bleeding (87.5%), mucus diarrhea (58.2%) and abdominal pain (37.5%). According to the Histopathologic study, there were 14 (58%) adenomas with carcinoma and the existence of carcinoma was proportional to the adenoma's size, we didn't find carcinoma in the adenomas smaller than 2 cm. The endoscopy was useful to detect invasive carcinoma in the 88% of cases meanwhile the endoscopic biopsy detected only 27% of cases. The endoscopic polipectomy was suitable when the adenomas were smaller than 3 cm.

Adenoma↗
PubMedDate not supplied

[Clinical evaluation of the use of proglumide in the treatment of the peptic ulcer semebrome].

The authors have made a clinical evaluation of Proglumida in 27 patients suffering from Peptic ulcer. Proglumida was administered orraly, 2 tables of 200 mg 3 times a day, 1.200 mg in 24 hours, during a period varying from 21 to 28 days. The painful symptoms improved in 96% of the pain occurred in 59% during the first 7 days of treatment. The dispeptic symptoms improved in all cases, disappearing completely in 74%, but in a slower fashion than the pain, and in 68% of the cases only from the second week of treatment onward. The objectivation of the pain by palpation of the epigastrium improved in all cases and did so in a significant form in 59% of the cases during the first seven days of treatment. No undesireable side effects have been observed in any of the cases. We believe that Proglumida is a pharmacological drug of positive action in the treatment of the ulcer syndrome, because of its favorable action and the absence of secondary side effects.

Adolescent↗